期刊文献+

帕金森病药物治疗中的若干问题 被引量:2

原文传递
导出
摘要 帕金森病(Parkinson's disease,PD)的药物治疗一直是临床研究和实践中的关注重点。近年来,伴随着PD治疗指南的陆续制定,PD的药物治疗日趋规范和合理。然而不可否认的是,在药物治疗过程中,仍有一些棘手的问题尚未完全解决,一些新问题不断地出现,从左旋多巴诱发的异动症到近期硫丙麦角林引起的心脏瓣膜病变,事实一次次地告诉我们:伴随新型药物的问世和使用,以及我们对某些症状和体征的渐进认识,PD的药物治疗仍然是一个在宏观的总体原则下具有动态性、自我更新性特点,深刻体现与时俱进、不断发展理念的临床课题。
作者 陈生弟 王刚
出处 《中华神经科杂志》 CAS CSCD 北大核心 2008年第3期145-146,共2页 Chinese Journal of Neurology
  • 相关文献

参考文献12

  • 1陈生弟.帕金森病治疗指南[J].中华神经科杂志,2006,39(6):409-412. 被引量:102
  • 2Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskincsia (an evidence-based review ): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2006, 66: 983-995.
  • 3The National Collaborating Centre for Chronic Conditions. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006 : 60-110.
  • 4Horstink M, Tolosa E, BonucceUi U, et al. Review of the therapeutic management of Parkinson' s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part Ⅱ: late (complicated) Parkinson' s disease. EurJ Neurol, 2006, 13: 1186-1202.
  • 5Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson ' s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part Ⅰ : early (uncomplicated) Parkinson' s disease. Eur J Neurol, 2006, 13 : 1170-1185.
  • 6Murata M, Hasegawa K, Kanazawa I; The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology, 2007, 68: 45-50.
  • 7Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson' s disease. Expert Opin Investig Drugs, 2005, 14: 729-738.
  • 8Muller T. Dopaminergic substitution in Parkinson' s disease. Expert Opin Pharmacother, 2002, 3 : 1393-1403.
  • 9Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson' s disease. Nat Clin Pract Neurol, 2006, 2: 382-392.
  • 10Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson' s disease therapy. Ann Neurol, 2003, 53 Suppl 3 : S3- S12.

二级参考文献16

  • 1Parkinson Study Group.Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.N Engl J Med,1993,328:176-183.
  • 2Riederer P,Lachenmayer L.Selegiline's neuroprotective capacity revisited.J Neural Transm,2003,110:1273-1278.
  • 3Shults CW,Oakes D,Kieburtz K,et al.Effects of coenzyme Q10 in early Parkinson disease:evidence of slowing of the functional decline.Arch Neurol,2002,59:1541-1550.
  • 4Albin RL,Frey KA.Initial agonist treatment of Parkinson disease.Neurology,2003,60:390-394.
  • 5Olanow W,Schapira AH,Rascol O.Continuous dopamine-receptor stimulation in early Parkinson's disease.Trends Neurosci,2000,23(10 Suppl):S117-S126.
  • 6Olanow CW,Watts RL,Koller WC.An algorithm (decision tree)for the management of Parkinson's disease (2001):treatment guidelines.Neurology,2001,56(11 Suppl 5):S1-S88.
  • 7Junghanns S,Glockler T,Reichmann H.Switching and combining of dopamine agonists.Neurol,2004,251 Suppl 6:VI/19-23.
  • 8Olanow CW,Stocchi F.COMT inhibitors in Parkinson's disease can they prevent and/or reverse levodopa-induced motor complications?Neurology,2004,62 Suppl 1:S72-S81.
  • 9Waters C.Other pharmacological treatments for motor complications and dyskinesias.Mov Disord,2005,20 Suppl Ⅱ:S38-S44.
  • 10Shiraishi M,Kamo T,Hotta M,et al.Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.J Neural Transm,2004,111:725-732.

共引文献101

同被引文献20

  • 1李彦杰,张文学,赵国华,王震宇.帕金森病三期辨治初探[J].中国中医基础医学杂志,2004,10(8):51-52. 被引量:9
  • 2Kwon D H, Kim J M, Oh S H, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease[J]. Ann Neurol, 2012,71(2):267.
  • 3Zhang Zhen-Xin, Gustavo C Roman, Zhen Hong, et al. Parkinson's disease in China: prevalence in Beijing, Xian and Shanghai[ J] Lancet ,2005 ( 365 ) :595.
  • 4Przedborski S, Isch iropou los H. Reactive oxygen and n itrogen species: weapons of neuronal destruction in models of Parkinson's disease [ J ]. Antioxid Redox Signal, 2005, 7 (5/6) : 685.
  • 5Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link[ J]. Exp Neurol, 2005, 193(2): 279.
  • 6Buchmann C,Arlt S,Kontush A, et al. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influence by antiparkinsonian medicine[J]. Neurobiol Dis ,2004 ( 15 ) : 160.
  • 7Maragakis N J, Jack son M, Ganel R, et al. Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice[J]. NeurosciLett, 2003, 338(2): 107.
  • 8Sanchez-Iglesias S, Rey P, Mendez-Alvarez E, et al. Time course of brain oxidative damage caused by intrastriatal administration of 6- hydroxydopamine in a rat model of Park inson's disease [ J]. Neurochem Res, 2007, 32(1): 99.
  • 9Yuan H, Sarre S, Ebinger G, et al. Histological, behavioural and Neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA Lesions as rat models of Parkinson s disease [ J ] J Neurosei Methods, 2005,144(1) :35.
  • 10Shiman R, Akino M. So lubilization and Partial Purification of Tyr- osine Hydroxy lase From Boy ine Adrenal Medulla [ J ]. Biol Chem, 1971, 246 (5) : 1330.

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部